Audit: QRS - Omaveloxolone for Health & Longevity
Audit conducted on 09/10/2026 14:06 using AI4L / Opus 5.5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 86 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Lede, protocol cells, time-to-effect cells, tier items, gates, markers, cadence and qualitative items all trace to ER Conclusion, Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks, Key Interactions and Monitoring passages. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “(theoretical)” kept for St John’s wort, statins, acetaminophen/alcohol, Nrf2 supplements, goldenseal; “(caution)” kept for pregnancy, breastfeeding, kidney impairment; “only nominally significant” and “exploratory” kept in time cells. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No ER claim strengthened or softened; “Avoid”, “Monitor”, “Caution” verdicts match ER wording. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from “Populations who should avoid”; interactions from the interaction bullets; tiers match ER tiers. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, expert names, NCT IDs or brand names appear. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-qualified tone mirrors the ER. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and objective, plainly worded, states benefit and limits without alarmism. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents facts and ER verdicts rather than orders. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No clinical advice beyond ER-derived verdicts; footer disclaimer is template text. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information is presented; verdict words come verbatim from the ER. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No “you”/”your” anywhere. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Lede and tier items in plain language; technical terms limited to ER labels, thresholds and marker names. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Items stripped to key facts. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct reader address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content (monitoring, interactions, healthy-adult evidence gap) suits risk-aware, proactive adults. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents a demanding protocol (fasting dosing, lab schedule) without dumbing down. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Lede separates the Friedreich’s ataxia signal from the absence of healthy-adult evidence (line 433). |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No “anti-aging” wording. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | “prescription oral medication” and “orally” used; no lay route terms. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and column headers unchanged (lines 440, 477, 519, 539, 554, 578, 597, 601-603, 716). |
| 3.2 | All “<span data-qrs-var="NAME">...</span>” from the [qrs_template] are present in the the QRS. |
🟢 | All 34 template span names present (marker_# and qualitative_item_# expanded to 9 and 6 instances). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Diff against template shows changes only in addressed spans and the hidden High tiers. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER source section mapped to a QRS section is empty; empty High tiers are governed by 12.5/13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Action labels (“Standard regimen”, “Reduced doses”, “Time of day”) and interaction bold labels use ER bold labels, trimmed only in their parenthetical lists. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels are ER labels or ER benefit headings; none invented. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji found in the file. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Sections condensed: interactions reduced to those changing use with trimmed example lists, tier items reduced to headings, markers to short targets. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. |
🟢 | Metadata comment is line 2, directly after doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by “—” at lines 3 and 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside an HTML comment; not surfaced elsewhere. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; only duration “00:01” is quoted (contains colon). |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: omaveloxolone_2026-1006-0252_Opus_ER.md |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.10.8 matches QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-1009-1349 |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5.5 |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5.5” = nickname + version. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename matches the file name. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Values trimmed; quoting only where required. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | “Omaveloxolone for Health & Longevity - Quick Reference Sheet” (line 22). |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | “Omaveloxolone for Health & Longevity” (line 417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 10/09/2026 from 2026-1009-1349 (line 421). |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Opus 5.5 (line 425). |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Only template header elements present. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Omaveloxolone is a prescription oral medication that switches on the body’s own antioxidant and anti-inflammatory defenses” and names its use in Friedreich’s ataxia. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the three Conclusion paragraphs: use, evidence limits, main risks, interactions, healthy-adult verdict. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 67 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each fact maps to ER Conclusion/Motivation passages (lines 38, 452, 454, 456). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; disease briefly explained. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, sizes or p-values. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | From ER Key Interactions & Contraindications “Populations who should avoid”. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All 8 ER populations listed (lines 542-549). |
| 8.3 | Individual [stop_items] are formatted as <li></li> |
🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing rationales (“given animal developmental toxicity”, “a trial exclusion”) stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Child-Pugh Class C, (caution), BNP/LVEF thresholds and eGFR threshold preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in this list. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated; ER names populations to avoid. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention --> |
N/A | Section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | From ER Key Interactions & Contraindications bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | 12 use-changing interactions listed; no-change items (digoxin/metformin, QT drugs, cimetidine) omitted; no overlap with contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li> |
🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic and dosing tails stripped; only verdicts kept. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists and “(theoretical)”, “(high doses)”, “(supplement)” qualifiers preserved in trimmed form. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | ER uses no ranking notation in interaction bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated; ER names use-changing interactions. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used --> |
N/A | Section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from ER Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Standard regimen, reduced doses and empty-stomach timing are the key actionable aspects. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | ER provides at least three actionable aspects. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All label/value/sub spans filled with ER-derived content (lines 444-472). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Neurological decline (months/48 weeks), daily functioning (48 weeks), exercise efficiency (12 weeks) from ER Practical Considerations and Expected Benefits. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered Medium, Medium, Low benefit. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three time-to-effect aspects are available. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All time spans filled with ER-derived content (lines 483-511). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | From ER Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans used. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are ER headings only. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | benefits_high span set to display: none (line 521). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | From ER Potential Risks & Side Effects. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans used. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are ER headings only. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
🟢 | risks_high span set to display: none (line 580). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | From ER Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 9 ER table biomarkers listed (lines 607-705). |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Cadence filled from ER Monitoring cadence paragraph (line 710). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | From ER Monitoring qualitative markers. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 ER qualitative markers listed verbatim (lines 719-734). |
Issues 09/10/2026 14:06
Pass rate 100.00%. No issues found.
Issues 09/10/2026 14:00
- 1.2 / 1.3 — Cautious daily-function phrasing dropped: time_2_sub (line 500) reads “Daily-activity scores favored omaveloxolone at 48 weeks (nominally significant)”, dropping the ER’s “numerically favored” and “only nominally significant” (Expected Benefits, Better preserved daily functioning), which strengthens the claim.
Fixes 09/10/2026 14:00
- 1.2 / 1.3 — Cautious daily-function phrasing restored: Changed time_2_sub from “Daily-activity scores favored omaveloxolone at 48 weeks (nominally significant)” to “Daily-activity scores numerically favored omaveloxolone at 48 weeks (only nominally significant)”, matching the ER wording.
Issues 09/10/2026 13:57
- 11.2 — Time-to-effect not benefit-ranked: time_3 (lines 505-511, “Side effects & liver enzymes”) covers adverse effects rather than a benefit, while the Medium benefit “Better preserved daily functioning in Friedreich’s ataxia” (ER Expected Benefits, 48 weeks) is omitted in favor of the Low exercise benefit.
Fixes 09/10/2026 13:57
- 11.2 — Time-to-effect re-ranked by benefit: Replaced the side-effect cell with the Medium benefit “Daily functioning” (48 weeks, nominally significant) as time_2 and moved the Low exercise benefit (12 weeks) to time_3.
Issues 09/10/2026 13:53
- 4.5 — Sheet exceeds one A4 page: Key Interactions (lines 557-568, 12 items with long parentheticals, e.g. line 562), the long Cadence text (line 710) and the long action_2_sub (line 461) are not condensed enough, pushing the sheet well beyond one A4 page.
Fixes 09/10/2026 13:53
- 4.5 — Condensed overlong sections: Shortened action_2_sub, trimmed the example lists in the strong/moderate CYP3A4 inhibitor, inducer and hormonal contraceptive interaction items (qualifiers kept), and compressed the monitoring cadence text to reduce page length.
Issues 09/10/2026 13:50
- 1.2 / 9.5 — Statins theoretical qualifier dropped: The Key Interactions item “Statins (atorvastatin, simvastatin): Monitor” (QRS line 564) omits the ER’s “(theoretical)” qualifier (ER line 318), presenting a theoretical interaction as established.
Fixes 09/10/2026 13:50
- 1.2 / 9.5 — Statins theoretical qualifier restored: Changed the Key Interactions item from “Statins (atorvastatin, simvastatin): Monitor” to “… Monitor (theoretical)” to match the ER’s qualifier.